BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 21297673)

  • 1. Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party.
    Wachowiak J; Sykora KW; Cornish J; Chybicka A; Kowalczyk JR; Gorczyńska E; Choma M; Grund G; Peters C;
    Bone Marrow Transplant; 2011 Dec; 46(12):1510-8. PubMed ID: 21297673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II prospective study of treosulfan-based reduced-intensity conditioning in allogeneic HSCT for hematological malignancies from 10/10 HLA-identical unrelated donor.
    Michallet M; Sobh M; Milpied N; Bay JO; Fürst S; Harousseau JL; Mohty M; Nicolini FE; Labussière H; Tedone N; Morisset S; Vigouroux S; Baumgart J; Tabrizi R; Blaise D
    Ann Hematol; 2012 Aug; 91(8):1289-97. PubMed ID: 22362122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Allogeneic blood stem cell transplantation in high-risk patients after conditioning with treosulfan and fludarabine].
    Casper J; Wilhelm S; Steiner B; Wolff D; Grobe N; Hähling D; Hartung G; Hilgendorf I; Lück A; Junghanss C; Kahl C; Baumgart J; Pichlmeier U; Freund M
    Dtsch Med Wochenschr; 2005 Sep; 130(38):2125-9. PubMed ID: 16172951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies.
    Boztug H; Sykora KW; Slatter M; Zecca M; Veys P; Lankester A; Cant A; Skinner R; Wachowiak J; Glogova E; Pötschger U; Peters C
    Pediatr Blood Cancer; 2016 Jan; 63(1):139-48. PubMed ID: 26398915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen.
    Sanz J; Boluda JC; Martín C; González M; Ferrá C; Serrano D; de Heredia CD; Barrenetxea C; Martinez AM; Solano C; Sanz MA; Sanz GF;
    Bone Marrow Transplant; 2012 Oct; 47(10):1287-93. PubMed ID: 22327127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substitution of cyclophosphamide and busulfan by fludarabine, treosulfan and melphalan in a preparative regimen for children and adolescents with Shwachman-Diamond syndrome.
    Sauer M; Zeidler C; Meissner B; Rehe K; Hanke A; Welte K; Lohse P; Sykora KW
    Bone Marrow Transplant; 2007 Feb; 39(3):143-7. PubMed ID: 17211437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning.
    Casper J; Wolff D; Knauf W; Blau IW; Ruutu T; Volin L; Wandt H; Schäfer-Eckart K; Holowiecki J; Giebel S; Aschan J; Zander AR; Kröger N; Hilgendorf I; Baumgart J; Mylius HA; Pichlmeier U; Freund M
    J Clin Oncol; 2010 Jul; 28(20):3344-51. PubMed ID: 20498405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous busulfan-cyclophosphamide as a preparative regimen before allogeneic hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia.
    Tang W; Wang L; Zhao WL; Chen YB; Shen ZX; Hu J
    Biol Blood Marrow Transplant; 2011 Oct; 17(10):1555-61. PubMed ID: 21549217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies.
    Pedrazzoli P; Da Prada GA; Giorgiani G; Schiavo R; Zambelli A; Giraldi E; Landonio G; Locatelli F; Siena S; Della Cuna GR
    Cancer; 2002 May; 94(9):2409-15. PubMed ID: 12015766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications.
    Beelen DW; Trenschel R; Casper J; Freund M; Hilger RA; Scheulen ME; Basara N; Fauser AA; Hertenstein B; Mylius HA; Baumgart J; Pichlmeier U; Hahn JR; Holler E
    Bone Marrow Transplant; 2005 Feb; 35(3):233-41. PubMed ID: 15592494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idarubicin-intensified BUCY2 regimens may lower relapse rate and improve survival in patients undergoing allo-SCT for high-risk hematological malignancies: a retrospective analysis.
    Hong M; Wu Q; Hu C; Fang J; You Y; Zhong Z; Zou P; Hu Y; Xia L
    Bone Marrow Transplant; 2012 Feb; 47(2):196-202. PubMed ID: 21441957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).
    Kröger N; Shimoni A; Zabelina T; Schieder H; Panse J; Ayuk F; Wolschke C; Renges H; Dahlke J; Atanackovic D; Nagler A; Zander A
    Bone Marrow Transplant; 2006 Feb; 37(4):339-44. PubMed ID: 16415898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.
    Devine SM; Sanborn R; Jessop E; Stock W; Huml M; Peace D; Wickrema A; Yassine M; Amin K; Thomason D; Chen YH; Devine H; Maningo M; van Besien K
    Bone Marrow Transplant; 2001 Sep; 28(6):557-62. PubMed ID: 11607768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
    Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
    Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
    Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
    Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide.
    Worth L; Tran H; Petropoulos D; Culbert S; Mullen C; Roberts W; Przepiorka D; Chan K
    Bone Marrow Transplant; 1999 Nov; 24(9):947-52. PubMed ID: 10556952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience.
    Wall DA; Carter SL; Kernan NA; Kapoor N; Kamani NR; Brochstein JA; Frangoul H; Goyal RK; Horan JT; Pietryga D; Wagner JE; Kurtzberg J;
    Biol Blood Marrow Transplant; 2005 Aug; 11(8):637-46. PubMed ID: 16041314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 5-day cytoreductive chemotherapy followed by haplo-identical hsct (FA5-BUCY) as a tumor-ablative regimen improved the survival of patients with advanced hematological malignancies.
    Yang T; Lin Q; Ren J; Chen P; Yuan X; Luo X; Liu T; Zheng J; Zheng Z; Zheng X; Chen X; Zhang L; Zheng H; Chen Z; Hua X; Le S; Li J; Chen Z; Hu J
    Oncotarget; 2016 Nov; 7(48):78773-78786. PubMed ID: 27705929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treosulfan-containing regimens achieve high rates of engraftment associated with low transplant morbidity and mortality in children with non-malignant disease and significant co-morbidities.
    Greystoke B; Bonanomi S; Carr TF; Gharib M; Khalid T; Coussons M; Jagani M; Naik P; Rao K; Goulden N; Amrolia P; Wynn RF; Veys PA
    Br J Haematol; 2008 Jun; 142(2):257-62. PubMed ID: 18492115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.